Arginine catabolism metabolites and atrial fibrillation or heart failure risk: 2 case-control studies within the Prevención con Dieta Mediterránea (PREDIMED) trial

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Goni, Leticia
• dc.contributor.author Fitó Colomer, Montserrat
• dc.contributor.author Ruiz-Canela, Miguel
• dc.date.accessioned 2024-04-10T07:00:46Z
• dc.date.available 2024-04-10T07:00:46Z
• dc.date.issued 2022
• dc.description.abstract Background Arginine-derived metabolites are involved in oxidative and inflammatory processes related to endothelial functions and cardiovascular risks. Objectives We prospectively examined the associations of arginine catabolism metabolites with the risks of atrial fibrillation (AF) or heart failure (HF), and evaluated the potential modifications of these associations through Mediterranean diet (MedDiet) interventions in a large, primary-prevention trial. Methods Two nested, matched, case-control studies were designed within the Prevención con Dieta Mediterránea (PREDIMED) trial. We selected 509 incident cases and 547 matched controls for the AF case-control study and 326 cases and 402 matched controls for the HF case-control study using incidence density sampling. Fasting blood samples were collected at baseline and arginine catabolism metabolites were measured using LC-tandem MS. Multivariable conditional logistic regression models were applied to test the associations between the metabolites and incident AF or HF. Interactions between metabolites and intervention groups (MedDiet groups compared with control group) were analyzed with the likelihood ratio test. Results Inverse association with incident AF was observed for arginine (OR per 1 SD, 0.83; 95% CI: 0.73–0.94), whereas a positive association was found for N1-acetylspermidine (OR for Q4 compared with Q1 1.58; 95% CI: 1.13–2.25). For HF, inverse associations were found for arginine (OR per 1 SD, 0.82; 95% CI: 0.69–0.97) and homoarginine (OR per 1 SD, 0.81; 95% CI: 0.68–0.96), and positive associations were found for the asymmetric dimethylarginine (ADMA) and symmetric dimethlyarginine (SDMA) ratio (OR per 1 SD, 1.19; 95% CI: 1.02–1.41), N1-acetylspermidine (OR per 1 SD, 1.34; 95% CI: 1.12–1.60), and diacetylspermine (OR per 1 SD, 1.20; 95% CI: 1.02–1.41). In the stratified analysis according to the dietary intervention, the lower HF risk associated with arginine was restricted to participants in the MedDiet groups (P-interaction = 0.044). Conclusions Our results suggest that arginine catabolism metabolites could be involved in AF and HF. Interventions with the MedDiet may contribute to strengthen the inverse association between arginine and the risk of HF. This trial was registered at controlled-trials.com as ISRCTN35739639.
• dc.description.sponsorship Supported by National Heart, Lung, and Blood Institute research grant R01HL118264 (to FBH). The PREDIMED (Prevención con Dieta Mediterránea) trial was supported by the official funding agency for biomedical research of the Spanish government, Instituto de Salud Carlos III, through grants provided to research networks specifically developed for the trial: RTIC G03/140 (to RE) during 2003–2005 and RTIC RD 06/0045 (to MAM-G) during 2006–2013 and through Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (to MAM-G); Centro Nacional de Investigaciones Cardiovasculares grant CNIC 06/2007; Fondo de Investigación Sanitaria—Fondo Europeo de Desarrollo Regional grants PI04-2239, PI 05/2584, CP06/00100, PI07/0240, PI07/1138, PI07/0954, PI 07/0473, PI10/01407, PI10/02658, PI11/01647, P11/02505, PI13/00462, and JR17/00022; Ministerio de Ciencia e Innovación grants AGL-2009-13906- C02, AGL2010-22319-C03, and SAF2016-80532-R; Fundación Mapfre 2010 (which had no role in the design, implementation, analysis, or interpretation of the data); Consejería de Salud de la Junta de Andalucía grant PI0105/2007; Public Health Division of the Department of Health of the Autonomous Government of Catalonia; Generalitat Valenciana grants ACOMP06109, GVA-COMP2010-181, GVACOMP2011-151, CS2010-AP111, PROMETEO 17/2017, and CS2011-AP-042; Fundació La MaratóTV3 (which had no role in the design, implementation, analysis, or interpretation of the data) grants 294/C/2015 and 538/U/2016; and Regional Government of Navarra grant P27/2011.
• dc.format.mimetype application/pdf
• dc.identifier.citation Goni L, Razquin C, Toledo E, Guasch-Ferré M, Clish CB, Babio N, et al. Arginine catabolism metabolites and atrial fibrillation or heart failure risk: 2 case-control studies within the Prevención con Dieta Mediterránea (PREDIMED) trial. Am J Clin Nutr. 2022 Sep 2;116(3):653-62. DOI: 10.1093/ajcn/nqac139
• dc.identifier.doi http://dx.doi.org/10.1093/ajcn/nqac139
• dc.identifier.issn 0002-9165
• dc.identifier.uri http://hdl.handle.net/10230/59719
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof Am J Clin Nutr. 2022 Sep 2;116(3):653-62
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/AGL2009-13906-C02
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PN/AGL2010-22319-C03
• dc.relation.projectID info:eu-repo/grantAgreement/ES/1PE/SAF2016-80532-R
• dc.rights © Elsevier http://dx.doi.org/10.1093/ajcn/nqac139
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.subject.keyword Arginine catabolism metabolites
• dc.subject.keyword Metabolomics
• dc.subject.keyword Atrial fibrillation
• dc.subject.keyword Heart failure
• dc.subject.keyword Mediterranean diet
• dc.subject.keyword Case-control
• dc.title Arginine catabolism metabolites and atrial fibrillation or heart failure risk: 2 case-control studies within the Prevención con Dieta Mediterránea (PREDIMED) trial
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/acceptedVersion